Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
QIFENG
873169
5
LAISAI LASER
871263
US OptionsDetailed Quotes
CGON250516C7500
- 0.00
- 0.000.00%
15min DelayClose May 9 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover354.40%IV-68.41%PremiumMay 16, 2025Expiry Date16.24Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9983Delta0.0005Gamma1.46Leverage Ratio-0.0046Theta0.0011Rho1.46Eff Leverage0.0002Vega
CG Oncology Newsroom
J.P. Morgan Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $41
Analysts' Opinions Are Mixed on These NA Stocks: Reddit Inc Class A (RDDT) and CG Oncology, Inc. (CGON)
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $68
BofA Securities Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $63
CG Oncology Is Maintained at Outperform by RBC Capital
CG Oncology Analyst Ratings
Buy Rating for CG Oncology, Inc. Driven by Cretostimogene's Potential in Bladder Cancer Treatment Amid BCG Shortage
RBC Raises Price Target on CG Oncology to $68 From $66, Keeps Outperform, Speculative Risk
CG Oncology Price Target Maintained With a $75.00/Share by Cantor Fitzgerald
CG Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
Buy Rating for CG Oncology, Inc.: Promising Efficacy and Competitive Positioning in NMIBC Treatment
Scotiabank Initiates CG Oncology(CGON.US) With Hold Rating, Announces Target Price $23
CG Oncology Analyst Ratings
Scotiabank Initiates CG Oncology at Sector Perform With $23 Price Target
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $82
Buy Rating Affirmed for CG Oncology Amid Promising Trial Data and Market Opportunities
TD Cowen Maintains CG Oncology(CGON.US) With Buy Rating
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $75
Morgan Stanley Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $55
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now